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Transient problems mainly occurred after high dose to the 
laryngeal and lower pharyngeal regions, combined with 
moderate dose to the upper pharyngeal region. The 
progressive pattern was mainly seen after moderate dose to 
the upper pharyngeal region. 
 
 
Conclusions: After definitive RT or CRT, five different 
patterns of swallowing dysfunction can be identified over 
time. This could reflect different underlying radiobiological 
mechanisms of radiation-induced damage and recovery. 
These results may improve identifying patients who are at 
the highest risk for developing severe persistent swallowing 
problems and who may benefit most from different 
preventive measures, such as swallowing sparing IMRT.  
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Purpose/Objective: Head and neck carcinoma of unknown 
primary (HNCUP) metastatic to cervical lymph nodes (LNs) 
constitutes about 2% of all head and neck carcinomas. There 
is no consensus on a standard radiotherapy clinical target 
volume (CTV) (ipsilateral neck only vs bilateral neck and 
mucosal tube) or dose to the CTV (50-70Gy). The aim of this 
combined analysis was to assess the safety and feasibility of 
total mucosal and bilateral neck intensity modulated 
radiotherapy (TM-IMRT). 
Materials and Methods: We performed a combined analysis 
of 2 single arm, phase 2 prospective trials (CCR2823 and 
CCR3301). All patients (pts) had PET-CT or CT staging, pan-
endoscopy and tonsillectomy or biopsy to exclude an occult 
primary. Patients with stage T0, N1-3, M0 (AJCC TNM 2002) 
disease were treated using a 5- to 7-field IMRT technique. 
CTV1 was the ipsilateral level 1b-5 and retropharyngeal (RP) 
LNs. CTV2 was the mucosa of nasopharynx, oropharynx, 
larynx, hypopharynx and contralateral cervical level 2 to 5 
and RP LNs. Prescribed doses to PTV1 and PTV2 in 30 
fractions were 60-65 Gy (depending on resection status R0 – 
60Gy, R1/R2 – 65 Gy) and 54 Gy, respectively. No 
prophylactic enteric feeding tubes were inserted. 
Results: Thirty-six pts (53% male) with HNCUP, median age of 
54.2 years (range 43-86.9 years), were treated between July 
2007 and December 2012. Histology was squamous cell 
carcinoma (SCC) in 35 pts or undifferentiated carcinoma 
nasopharyngeal type in 1 pt. Twenty-five (69%) pts were p16-
positive (surrogate for HPV) and 18 (50%) pts had a ≥10 pack 
year smoking history. Eighteen (50%) pts received 
chemoradiotherapy with concomitant platinum and 18 
(50%)pts radiotherapy (RT) alone. The median treatment time 
was 41 days (range 39-46 days). All pts received the 
prescribed dose with no clinically significant delays. The 2 
year locoregional control rate was 89.8% (95% CI, 78.4-100). 
The 2 year primary mucosal and local nodal control rates 
were 97.1% (95% CI, 91.4-100) and 89.8% (95% CI, 78.4-100) 
respectively. One mucosal primary (oropharynx) was 
detected 7.3 months (m) after RT and 2 patients died from 
recurrent metastatic SCC at 5.7m and 16.4m after RT. 
Twelve pts (33%) had acute (<3m after RT) grade 3 (LENT-
SOMA) dysphagia. The 1 year enteric tube feeding rate was 1 
of 36 (2.7%) pts. Rates of high grade, subjective xerostomia 
(LENT-SOMA, ≥grade 2) at 12m and 24m after RT were 17% 
and 15% respectively. 
Conclusions:At a median follow up of 33.5 months the use of 
TM-IMRT treating the total mucosal tube to an elective 
radiation dose of 54 Gy was associated with good local 
control rates. Toxicity is improved compared to previously 
reported TM-IMRT regimens encompassing similar mucosal 
volumes.  
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Purpose/Objective: Tumor hypoxia is a common feature of 
locally advanced head and neck cancer (HNSCC) that is 
associated with higher malignancy and increased 
radioresistance. The resolution of tumor hypoxia during 
fractionated radiation treatment is assumed to be pivotal for 
treatment success. 18F-fluoromisonidazole PET (F-MISO PET) 
allows noninvasive assessment of hypoxia during treatment. 
The purpose of the present study was to noninvasively assess 
the time course of tumor hypoxia and its correlation with 
additional imaging modalities and outcome. 
Materials and Methods: A prospective serial imaging study 
was conducted in patients undergoing definitive 
radiochemotherapy (RCTx, total dose 70Gy) for locally 
advanced HNSCC, accompanied by Cisplatin in weeks 1, 4 and 
7. Tumor hypoxia was assessed by F-MISO-PET by static scans 
acquired 2.5 h p.i. Tumor volumes were determined for FDG 
PET scans and the coregistered F-MISO scans. At baseline MRI, 
FDG-PET and 1st F-MISO were acquired. Additional F-MISO 
scans were acquired in treatment weeks 2 and 5 (F-MISO2, 3). 
Endpoints were standardized uptake values (SUV) for PET 
scans, response on MRI scans (complete reponse (CR), partial 
